Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 206

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 206
---
2024Operating expenses:Cost of sales$1,679 $783 $4,466 $2,905 Research and development86,796 72,455 251,479 218,476 Selling, general and administrative41,274 38,537 128,670 105,087 Total operating expenses$129,749 $111,775 $384,615 $326,468 

Total Operating Expenses -  Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 – The increase in total operating expenses of $18.0 million for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 was primarily due to an increase in research and development expenses of $14.3 million, which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $2.7 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

Total Operating Expenses -  Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 – The increase in total operating expenses of $58.1 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily due to an increase in research and development expenses of $33.0 million which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $23.6 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

26

Research and Development Expenses

Our research and development expenses, by major program, are outlined in the table below:Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024PK activator (PYRUKYND®)$30,533 $26,829 $81,663 $80,833 Novel PK activator (tebapivat)8,498 3,768 21,738 10,151 In-process research and development— — 10,000 — Other research and platform programs6,668 4,316 15,506 15,271 Total direct research